



OFFICE of the DEPUTY PRIME MINISTER
MINISTRY for HEALTH
15, PALAZZO CASTELLANIA, MERCHANTS STREET, VALLETTA, MALTA

DH Circular 80/2020
DH 1025/2020

17th November 2020

Attention All: Consultants
Medical Officers
Pharmacists
Pharmacy Technicians
Nurses

Re: Lenalidomide 5mg, 10mg and 15mg Capsules

As part of Government's ongoing plan to increase the availability of oncology drugs, it is being brought to your attention that lenalidomide 5mg, 10mg and 15mg capsules are now available on the Government Formulary List for in-patient use and out-patient use, in addition to the currently available 25mg dose.

Lenalidomide capsules can be prescribed by Consultant Haematologists and Consultant Oncologists for multiple myeloma, myelodysplastic syndrome, and non-Hodgkin's lymphoma as per protocol 263 (Annex 1) attached.

For your attention please.

Dr. Denis Vella Baldacchino
Chief Medical Officer

Lenalidomide 5mg, 10mg, 15mg and 25mg Capsules

Prescriber Criteria: Consultant Haematologist
Consultant Oncologist

Out-patient and In-patient use:

1. Malignant Diseases

- ***Multiple Myeloma***

To be used:

- As monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.
- As combination therapy with dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant, or who are intolerant to thalidomide.
- In combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.

- ***Myelodysplastic Syndrome***

To be used as monotherapy for the treatment of adult patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

- ***Non-Hodgkin's Lymphoma***

For the treatment of adult patients with relapsed or refractory non-Hodgkin's lymphoma

Duration of Approval:

1 year